ClinicalTrials.gg
CompletedNCT04368988Updated Apr 10, 2023

Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant

A Phase 1/2 interventional study of SARS-CoV-2 rS - Phase 1 and SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1 in COVID-19, sponsored by Novavax. Completed at 18 sites in 2 countries. Open to participants aged 18 Years to 84 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-10.

Sponsored by Novavax · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 5 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2023.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,419
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.

Enrollment
6th of 18
1,419 · median 997
Started
2020
with 3 others
Phase 1/2
Only one
of the 18
Registered
1st of 18
by date
Lead sponsor
12 of 18
Novavax

Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 6th largest by enrollment, is one of 4 that started in 2020, is the only one in phase 1/2, and was the 1st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →

About NVX-CoV2373 adjuvated lipid nanoparticle

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 as a file.
02

Study summary

2019nCoV-101 is a 2-part, randomized, observer-blinded, placebo-controlled, Phase 1/2 trial. Part 1 (Phase 1) of the study is designed to evaluate the safety and immunogenicity of SARS-CoV-2 rS nanoparticle vaccine with or without Matrix-M adjuvant in 131 healthy participants ≥ 18 to 59 (inclusive) years of age at 2 sites in Australia. An interim analysis of Part 1 safety and immunogenicity will be performed prior to optional expansion to Part 2. Part 2 (Phase 2) of the study is designed to evaluate the immunogenicity, safety, and preliminary efficacy of a single construct of SARS-CoV-2 rS nanoparticle vaccine with Matrix-M adjuvant in up to 1,500 healthy participants ≥ 18 to 84 (inclusive) years of age at up to 40 sites across Australia and/or the United States.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (Part 1):

  • Healthy adult males or females between 18 and 59 years of age, inclusive, at screening. Healthy status will be determined by the investigator based on medical history, clinical laboratory results, vital sign measurements, and physical examination at screening.
  • The participant has a 17 to 35 kg/m2, inclusive, at screening.
  • Willing and able to give prior to study enrollment and comply with study procedures.
  • Female participants of (defined as any female who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or [defined as amenorrhea at least 12 consecutive months or documented plasma follicle-stimulating hormone (FSH) level ≥40 mIU/mL]) must agree to be heterosexually inactive from at least 21 days prior to enrollment and through 6 months after the last vaccination OR agree to consistently use any of the described methods of from at least 21 days prior to enrollment and through 6 months after the last vaccination.

Exclusion Criteria (Part 1):

  • Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care, inclusive of changes in medication in the past 2 months indicating that chronic illness/disease is not stable (at the discretion of the investigator). This includes any current workup of undiagnosed illness that could lead to a new condition.
  • Chronic disease inclusive of: a) hypertension uncontrolled for age according to the Eighth Joint National Committee (JNC 8) guidelines; b) congestive heart failure by (NYHA) functional classification of greater or equal to II; c) by Global Initiative for Obstructive Lung Disease (GOLD) classification of greater or equal to 2; d) recent (within 6 months prior to first study vaccination) exacerbation of coronary artery disease as manifested by cardiac intervention, addition of new cardiac medications for control of symptoms, or unstable angina; e) asthma (diagnosed by spirometry showing reversibility of disease and must meet at least the Step 1 classification with current prescription/use of medications to control symptoms); f) diabetes requiring use of medicine (insulin or oral) or not controlled with diet.
  • Participation in research involving an product (drug/biologic/device) within 45 days prior to first study vaccination.
  • History of a confirmed diagnosis of SARS or COVID-19 disease (confirmed by a specific test for each disease) or known exposure to a SARS-CoV-2 positive confirmed close contact (eg, family member, housemate, daycare provider, aged parent requiring care), at the discretion of the investigator.
  • Currently working in an occupation with a high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response personnel).
  • Currently taking any product (investigational or off-label) for prevention of COVID-19 disease.
  • Positive rapid test for SARS-CoV-2 (either ELISA IgG or PCR) at screening or prior to first vaccination. Testing may be repeated during the screening period if exposure to SARS-CoV-2 is suspected, at the discretion of the investigator.
  • Received influenza vaccination within 14 days prior to first study vaccination, or any other vaccine within 4 weeks prior to first study vaccination.
  • Any or immunodeficiency disease/condition (iatrogenic or congenital).
  • Chronic administration (defined as more than 14 continuous days) of , systemic glucocorticosteroids, or other immune-modifying drugs within 90 days prior to first study vaccination; or anticipation of the need for immunosuppressive treatment within 6 months after last vaccination.
  • Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination.
  • Any acute illness concurrent or within 14 days prior to first study vaccination (medical history and/or physical examination) or documented temperature of >38°C during this period. This includes respiratory or constitutional symptoms consistent with SARS-CoV-2 (COVID-19) exposure (ie, cough, sore throat, difficulty breathing).
  • Known disturbance of coagulation (iatrogenic or congenital).
  • Evidence of or C or by laboratory testing.
  • A positive test result for drugs of abuse (except a positive test result associated with prescription medication that has been reviewed and approved by the investigator) or alcohol at screening.
  • Any neurological disease or history of significant neurological disorder (eg, meningitis, seizures, multiple sclerosis, vasculitis, migraines, Guillain-Barré syndrome [genetic/congenital or acquired]).
  • Active cancer () within 5 years prior to first study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma, at the discretion of the investigator)
  • Vital sign (blood pressure, pulse, temperature) abnormalities of toxicity grade >1.
  • Clinical laboratory abnormalities of toxicity grade >1 for selected serum chemistry and hematology parameters
  • Any known allergies to products contained in the investigational product or latex allergy.
  • Women who are pregnant, breastfeeding or who plan to become pregnant during the study.
  • History of alcohol abuse or drug addiction within 1 year prior to the first study vaccination.
  • Any condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
  • Study team member or first-degree relative of any study team member (inclusive of sponsor, PPD, and site personnel involved in the study).

Inclusion Criteria (Part 2):

  • Healthy adult males or females between 18 and 84 years of age, inclusive, at screening who are of legal adult age in their local jurisdiction. Healthy status will be determined by the investigator based on medical history, clinical laboratory results, vital sign measurements, and physical examination at screening.
  • The participant has a body mass index 17 to 35 kg/m2, inclusive, at screening.
  • Willing and able to give informed consent prior to study enrollment and comply with study procedures.
  • Female participants of childbearing potential (defined as any female who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months or documented plasma FSH level ≥40 mIU/mL]) must agree to be heterosexually inactive from at least 21 days prior to enrollment and through 6 months after the last vaccination OR agree to consistently use any of the following methods of contraception from at least 21 days prior to enrollment and through 6 months after the last vaccination.

Exclusion Criteria (Part 2):

  • Participants who are having any current workup of undiagnosed illness within the last 8 weeks, which is either participant-reported or has been clinician-assessed, that could lead to a new condition diagnosis.
  • Participation in research involving an investigational product (drug/biologic/device) within 45 days prior to first study vaccination.
  • History of a confirmed diagnosis of SARS or history of a confirmed diagnosis of COVID-19 disease resulting in medical intervention.
  • Received influenza vaccination within 14 days prior to first study vaccination, or any other vaccine within 4 weeks prior to first study vaccination.
  • Have chronic cardiovascular, endocrine, gastrointestinal/ hepatic, renal, neurological, respiratory, or other medical disorders not excluded by other exclusion criteria, that are assessed by the Investigator as being clinically unstable within the prior 4 weeks evidenced by: a) hospitalization for the condition, including day surgical interventions, b) new significant organ function deterioration, c) needing addition of new treatments or major dose adjustments of current treatments.
  • Diabetes mellitus requiring insulin therapy (either type 1 or type 2 diabetes mellitus).
  • Chronic obstructive pulmonary disease with a history of an acute exacerbation of any severity in the prior year.
  • Any history of congestive heart failure.
  • Any history of chronic kidney disease (the presence of impaired or reduced kidney function lasting at least 3 months). Clinical validation of potential cases of chronic kidney disease should be conducted.
  • Evidence of unstable coronary artery disease as manifested by cardiac intervention, addition of new cardiac medications for control of symptoms, or unstable angina in the past 3 months.
  • History of chronic neurological disorders that have required prior specialist physician review for diagnosis and management (such as multiple sclerosis, dementia, , Parkinson's disease, degenerative neurological conditions, neuropathy, and epilepsy) or a history of stroke or previous neurological disorder within 12 months with residual symptoms. Participants with a history of migraine or chronic headaches or nerve root compression that have been stable on treatment for the last 4 weeks are not excluded.
  • Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital).
  • Chronic administration (defined as more than 14 continuous days) of immunosuppressants, systemic glucocorticosteroids reaching an immunosuppressive dose, or other immune-modifying drugs within 90 days prior to first study vaccination.
  • Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination.
  • Known disturbance of coagulation (iatrogenic or congenital).
  • Active cancer (malignancy) within 5 years prior to first study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma, at the discretion of the investigator).
  • Any known allergies to products contained in the investigational product or latex allergy.
  • Women who are breastfeeding or who plan to become pregnant during the study.
  • History of alcohol abuse or drug addiction within one year prior to the first study vaccination.
  • Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
  • Study team member or first-degree relative of any study team member (inclusive of sponsor, PPD, and site personnel involved in the study).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,419 participants (actual)

Study arms

  • Placebo comparator
    Placebo - Phase 1

    2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.

    Other: Normal saline solution (NSS), Placebo - Phase 1

  • Experimental
    SARS-CoV-2 rS - 25 μg without Matrix-M - Phase 1

    2 doses of SARS-CoV-2 rS - 25 μg, 1 dose each on Days 0 and 21.

    Biological: SARS-CoV-2 rS - Phase 1

  • Experimental
    SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 1

    2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.

    Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1

  • Experimental
    SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 1

    2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for each injection), 1 dose each on Days 0 and 21.

    Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1

  • Experimental
    SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1

    1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (mixed together for injection), on Day 0 followed by 1 dose of Placebo on Day 21.

    Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1 · Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1

  • Placebo comparator
    Placebo - Phase 2

    3 doses of Placebo (Saline), 1 dose each on Days 0, 21, and 189.

    Other: Normal saline solution (NSS), Placebo - Phase 2

  • Experimental
    SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2

    2 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.

    Other: Normal saline solution (NSS), Placebo - Phase 2 · Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

  • Experimental
    SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2

    1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 1 dose of Placebo on Day 21 followed by 1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 189.

    Other: Normal saline solution (NSS), Placebo - Phase 2 · Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

  • Experimental
    SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2

    2 doses of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Days 0 and 21, followed by 1 dose of Placebo on Day 189.

    Other: Normal saline solution (NSS), Placebo - Phase 2 · Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

  • Experimental
    SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2

    1 dose of SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.

    Other: Normal saline solution (NSS), Placebo - Phase 2 · Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

  • Experimental
    SARS-CoV-2 rS - 5/5/5 μg + 50 μg Matrix-M - Phase 2

    3 doses of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated), 1 dose each on Day 0, Day 21, and Day 189.

    Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

  • Experimental
    SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2

    1 dose of SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M (co-formulated) on Day 0 then 2 doses of Placebo, 1 dose each on Days 21 and 189.

    Other: Normal saline solution (NSS), Placebo - Phase 2 · Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

Interventions

  • BiologicalSARS-CoV-2 rS - Phase 1

    Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS (0.6 mL) on Days 0 and 21.

  • BiologicalSARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1

    Drug page: NVX-CoV2373 adjuvated lipid nanoparticle

    Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Days 0 and 21.

    Also known as: NVX-CoV2373

  • OtherNormal saline solution (NSS), Placebo - Phase 1

    Alternating intramuscular (deltoid) injections of placebo (0.6 mL) on Days 0 and 21.

    Also known as: Sodium chloride solution for injection, 0.9%

  • OtherNormal saline solution (NSS), Placebo - Phase 2

    Intramuscular (deltoid) injections of placebo (0.5 mL).

    Also known as: Sodium chloride solution for injection, 0.9%

  • BiologicalSARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1

    Drug page: NVX-CoV2373 adjuvated lipid nanoparticle

    Intramuscular (deltoid) injection of SARS-CoV-2 rS mixed with Matrix-M adjuvant (0.6 mL) on Day 0.

    Also known as: NVX-CoV2373

  • OtherNormal saline solution (NSS), Placebo, Day 21 - Phase 1

    Intramuscular injection of placebo (0.6 mL) in alternate deltoid on Day 21.

    Also known as: Sodium chloride solution for injection, 0.9%

  • BiologicalSARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2

    Drug page: NVX-CoV2373 adjuvated lipid nanoparticle

    Intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL).

    Also known as: NVX-CoV2373

06

What researchers measure

Primary outcomes

  1. Participants with Solicited Adverse Events (AEs) - Phase 1

    Percentage of participants with solicited AEs (local, systemic) for 7 days following each primary vaccination (Days 0, 21) by severity score, duration, and peak intensity.

    Time frame: 28 days

  2. Safety Laboratory Values (Serum Chemistry, Hematology) - Phase 1

    Safety laboratory values (serum chemistry, hematology) by FDA toxicity scoring (absolute and change from baseline where identified) at 7 days after each vaccination.

    Time frame: 28 days

  3. Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs through Day 21.

    Time frame: 21 days

  4. Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs through Day 35.

    Time frame: 35 days

  5. Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs through Day 35.

    Time frame: 35 days

  6. Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs through Day 35. SCR is the proportion of participants with ≥4-fold rises in ELISA units.

    Time frame: 35 days

  7. Serum IgG Antibody Levels Expressed as GMEUs - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs for the two-dose regimens by dose at Day 35 regardless of baseline immune status and stratified by baseline immune status.

    Time frame: Day 35

  8. Serum IgG Antibody Levels Expressed as GMFRs - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs for the two-dose regimens by dose at Day 35 regardless of baseline immune status and stratified by baseline immune status.

    Time frame: Day 35

  9. Serum IgG Antibody Levels Expressed as SCRs - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs (≥4-fold rises) for the two-dose regimens by dose at Day 35 regardless of baseline immune status and stratified by baseline immune status.

    Time frame: Day 35

  10. Participants with Solicited Adverse Events (AEs) - Phase 2

    Percentage of participants with solicited AEs (local, systemic) for 7 days following each primary vaccination (Days 0 and 21) by severity score, duration, and peak intensity.

    Time frame: 28 days

  11. Participants with Unsolicited AEs - Phase 2

    Percentage of participants with unsolicited AEs (eg, treatment-emergent, serious, suspected unexpected serious, those of special interest, all medically attended adverse events \[MAAEs\]) through the 35 days by Medical Dictionary of Regulatory Activities (MedDRA) classification, severity score, and relatedness.

    Time frame: 35 days

Secondary outcomes

  1. Participants with Unsolicited AEs - Phase 1

    Percentage of participants with unsolicited AEs (eg, treatment-emergent, serious, suspected unexpected serious, those of special interest, all MAAEs) through the first 49 days by MedDRA classification, severity score, and relatedness.

    Time frame: 49 days

  2. Participants with Abnormal Vital Signs - Phase 1

    Percentage of participants with vital sign abnormalities on the day of vaccination by severity scoring immediately following vaccination.

    Time frame: 21 days

  3. Changes from Baseline in Body Temperature - Phase 1

    Mean changes from baseline in body temperature by treatment group and visit.

    Time frame: 189 days

  4. Changes from Baseline in Blood Pressure - Phase 1

    Mean changes from baseline in blood pressure by treatment group and visit.

    Time frame: 189 days

  5. Changes from Baseline in Pulse Rate - Phase 1

    Mean changes from baseline in pulse rate by treatment group and visit.

    Time frame: 189 days

  6. Participants with MAAEs - Phase 1

    Percentage of participants with MAAEs, defined as AEs that lead to an unscheduled visit to a healthcare practitioner, through Day 105 by MedDRA classification, severity score, and relatedness.

    Time frame: 105 days

  7. Participants with Related MAAEs; Serious Adverse Events (SAEs); and Adverse Events of Special Interest (AESI) - Phase 1

    Percentage of participants with MAAEs assessed as related to study vaccine, SAEs, and AESIs until the end of the study (EOS) by MedDRA classification and severity score. All SAEs and AESI, defined as potential immune-mediated medical conditions or AEs relevant to COVID-19, by MedDRA classification, severity score, and relatedness.

    Time frame: 386 days

  8. Assessment of Serum IgG Antibody Levels Expressed as GMTs at Multiple Time Points - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs at multiple time points through Day 189.

    Time frame: 189 days

  9. Assessment of Serum IgG Antibody Levels Expressed as GMFRs at Multiple Time Points - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at multiple time points through Day 189.

    Time frame: 189 days

  10. Assessment of Serum IgG Antibody Levels Expressed as SCRs at Multiple Time Points - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs (proportion of participants with ≥2-fold and ≥4-fold rises in antibody levels) at multiple time points through Day 189.

    Time frame: 189 days

  11. Assessment of Serum IgG Antibody Levels Expressed by Seroresponse Rates (SRRs) at Multiple Time Points - Phase 1

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SRRs (proportion of participants with rises in ELISA units exceeding the 95th percentile of placebo participants) at multiple time points through Day 189.

    Time frame: 189 days

  12. Angiotensin-Converting Enzyme 2 (ACE2) Receptor Binding Inhibition Assay Expressed as GMTs - Phase 1

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMTs at multiple time points through Day 189.

    Time frame: 189 days

  13. ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs - Phase 1

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMFRs at multiple time points through Day 189.

    Time frame: 189 days

  14. ACE2 Receptor Binding Inhibition Assay Expressed as SCRs - Phase 1

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as SCRs at multiple time points through Day 189.

    Time frame: 189 days

  15. ACE2 Receptor Binding Inhibition Assay Expressed as SRRs - Phase 1

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as SRRs at multiple time points through Day 189.

    Time frame: 189 days

  16. Neutralizing Antibody Activity Expressed as GMTs - Phase 1

    Neutralizing antibody activity as detected by microneutralization assay (MN) expressed as GMTs at multiple time points through Day 49.

    Time frame: 49 days

  17. Neutralizing Antibody Activity Expressed as GMFRs - Phase 1

    Neutralizing antibody activity as detected by MN expressed as GMFRs at multiple time points through Day 49.

    Time frame: 49 days

  18. Neutralizing Antibody Activity Expressed as SCRs - Phase 1

    Neutralizing antibody activity as detected by MN expressed as SCRs at multiple time points through Day 49.

    Time frame: 49 days

  19. Neutralizing Antibody Activity Expressed as SRRs - Phase 1

    Neutralizing antibody activity as detected by MN expressed as SRRs at multiple time points through Day 49.

    Time frame: 49 days

  20. Assessment of Cell-Mediated (T helper 1 [Th1]/T helper 2 [Th2]) Pathways - Phase 1

    Cell-mediated (Th1/Th2) pathways as measured by whole blood (flow cytometry) and/or in vitro peripheral blood mononuclear cell (PBMC) stimulation (eg, enzyme-linked immunospot \[ELISpot\], cytokine staining) with SARS-CoV-2 rS protein(s) through Day 28.

    Time frame: 28 days

  21. Assessment of Serum IgG Antibody Levels Expressed as GMTs - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs for the single-dose regimens compared to the two-dose regimens and to placebo through Day 35 regardless of baseline immune status and stratified by baseline immune status.

    Time frame: 35 days

  22. Assessment of Serum IgG Antibody Levels Expressed as GMFRs - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs for the single-dose regimens compared to the two-dose regimens and to placebo through Day 35 regardless of baseline immune status and stratified by baseline immune status.

    Time frame: 35 days

  23. Assessment of Serum IgG Antibody Levels Expressed as SCRs (≥ 4-fold change) - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs (≥ 4-fold change) for the single-dose regimens compared to the two-dose regimens and to placebo through Day 35 regardless of baseline immune status and stratified by baseline immune status.

    Time frame: 35 days

  24. Assessment of Serum IgG Antibody Levels Expressed as GMEUs at Multiple Time Points - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs at multiple time points through Day 357 for the single-dose regimens compared to the two-dose regimens and to placebo, stratified by baseline immune response.

    Time frame: 357 days

  25. Assessment of Serum IgG Antibody Levels Expressed as GMFRs at Multiple Time Points - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at multiple time points through Day 357 for the single-dose regimens compared to the two-dose regimens and to placebo, stratified by baseline immune response.

    Time frame: 357 days

  26. Assessment of Serum IgG Antibody Levels Expressed as SCRs (≥ 4-fold change) at Multiple Time Points - Phase 2

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs (≥ 4-fold change) at multiple time points through Day 357 for the single-dose regimens compared to the two-dose regimens and to placebo, stratified by baseline immune response.

    Time frame: 357 days

  27. ACE2 Receptor Binding Inhibition Assay Expressed as GMTs - Phase 2

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMTs at multiple time points through Day 357 for the single-dose regimens compared to the two-dose regimens and to placebo.

    Time frame: 357 days

  28. ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs - Phase 2

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMFRs at multiple time points through Day 357 for the single-dose regimens compared to the two-dose regimens and to placebo.

    Time frame: 357 days

  29. ACE2 Receptor Binding Inhibition Assay Expressed as SCRs - Phase 2

    Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as SCRs (≥ 4-fold change) at multiple time points through Day 357 for the single-dose regimens compared to the two-dose regimens and to placebo.

    Time frame: 357 days

  30. Neutralizing Antibody Activity Expressed as GMTs - Phase 2

    Neutralizing antibody activity as detected by MN expressed as GMTs at Days 35, 217, and 357 relative to baseline in a subset of subjects by absolute titers and change from baseline.

    Time frame: 357 days

  31. Neutralizing Antibody Activity Expressed as GMFRs - Phase 2

    Neutralizing antibody activity as detected by MN expressed as GMFRs at Days 35, 217 and 357 relative to baseline in a subset of subjects by absolute titers and change from baseline.

    Time frame: 357 days

  32. Neutralizing Antibody Activity Expressed as SCRs (≥ 4-fold change) - Phase 2

    Neutralizing antibody activity as detected by MN expressed as SCRs (≥ 4-fold change) at Days 35, 217, and 357 relative to baseline in a subset of subjects by absolute titers and change from baseline.

    Time frame: 357 days

  33. Assessment of Serum IgG Antibody Levels Expressed as GMTs - Phase 2 Boost

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs at Days 189, 217, and 357 for all treatment groups and additionally at Day 371 and Day 546 for treatment groups B and C for boosting assessment with either placebo or active boost.

    Time frame: 546 days

  34. Assessment of Serum IgG Antibody Levels Expressed as GMFRs - Phase 2 Boost

    Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Days 189, 217, and 357 for all treatment groups and additionally at Day 371 and Day 546 for treatment groups B and C for boosting assessment with either placebo or active boost.

    Time frame: 546 days

  35. Participants with MAAEs - Phase 2

    All MAAEs, defined as AEs that lead to an unscheduled visit to a healthcare practitioner, through Day 217 by MedDRA classification, severity score, and relatedness.

    Time frame: 217 days

  36. Participants with Related MAAEs; SAEs; and AESIs - Phase 2

    Percentage of participants with MAAEs assessed as related to study vaccine, SAEs, and AESIs until the end of the study (EOS) by MedDRA classification and severity score. All SAEs and AESI, defined as potential immune-mediated medical conditions or AEs relevant to COVID-19, by MedDRA classification, severity score, and relatedness.

    Time frame: 357 days

  37. Participants with Abnormal Vital Signs - Phase 2

    Percentage of participants with vital sign abnormalities on the day of vaccination by severity scoring immediately following vaccination. Descriptive statistics (mean, standard deviation, change from baseline) by treatment group, by visit.

    Time frame: 21 days

  38. Changes from Baseline in Body Temperature - Phase 2

    Mean changes from baseline in body temperature by treatment group and visit.

    Time frame: 189 days

  39. Changes from Baseline in Blood Pressure - Phase 2

    Mean changes from baseline in blood pressure by treatment group and visit.

    Time frame: 189 days

  40. Changes from Baseline in Pulse Rate - Phase 2

    Mean changes from baseline in pulse rate by treatment group and visit.

    Time frame: 189 days

  41. Participants with SARS-CoV-2 Positivity - Phase 2

    Percentage of participants with SARS-CoV-2 positivity as diagnosed by qualitative polymerase chain reaction (PCR) following COVID-19 symptoms assessment from Day 28 through 6 months with severity classification, overall and by age strata (18-59, 60-84 years).

    Time frame: 161 days

  42. Assessment of SARS-CoV-2 by Qualitative PCR - Phase 2

    Assessment of SARS-CoV-2 by qualitative PCR based on routine screening by self- collection (nasal mid-turbinate or saliva) from Day 28 through 6 months without symptomatology to further describe epidemiologic evolution of the pandemic and potential effect of vaccination.

    Time frame: 161 days

  43. Assessment of Cell-Mediated (Th1/Th2) Pathways - Phase 2

    Assessment of cell-mediated (Th1/Th2) pathways as measured by whole blood (flow cytometry) and/or in vitro PBMC stimulation (eg, ELISpot, cytokine staining) with SARS-CoV-2 rS protein(s) through Day 28.

    Time frame: 28 days

07

Study locations

18 sites
  • Meridian Clinical Research-(Savannah Georgia) - Platinum - PPDS - Phase 2
    Savannah, Georgia 31406, United States
  • Advanced Clinical Research - Meridian - ERN-PPDS - Phase 2
    Meridian, Idaho 83642, United States
  • Alliance for Multispecialty Research, LLC - Phase 2
    Newton, Kansas 67114, United States
  • Alliance for Multispecialty Research, LLC - Phase 2
    Wichita, Kansas 67207, United States
  • Central Kentucky Research Associates Inc - Phase 2
    Lexington, Kentucky 40509, United States
  • Meridian Clinical Research-(Rockville Maryland) - Platinum - PPDS - Phase 2
    Rockville, Maryland 20854, United States
  • Synexus Clinical Research US, Inc. - Cincinnati - Phase 2
    Cincinnati, Ohio 45236, United States
  • Rapid Medical Research Inc - ERN-PPDS - Phase 2
    Cleveland, Ohio 44122, United States
  • Paratus Clinical Research - Canberra - Phase 2
    Bruce, Australian Capital Territory 2617, Australia
  • Paratus Clinical Research - Western Sydney - Phase 2
    Blacktown, New South Wales 2148, Australia
  • Paratus Clinical Research - Central Coast - Phase 2
    Kanwal, New South Wales 2259, Australia
  • Australian Clinical Research Network - Phase 2
    Maroubra, New South Wales 2035, Australia
  • Scientia Clinical Research Limited - Phase 2
    Randwick, New South Wales 2031, Australia
  • Q Pharm Pty Limited - Phase 1
    Herston, Queensland 4006, Australia
  • University of the Sunshine Coast, Health Hub Morayfield - Phase 2
    Morayfield, Queensland 4506, Australia
  • University of the Sunshine Coast - Phase 2
    Sippy Downs, Queensland 4556, Australia
  • Barwon Health - Phase 2
    Geelong, Victoria 3220, Australia
  • Center for Clinical Studies - Phase 1 and Phase 2
    Melbourne, Victoria 3181, Australia
08

References and documents

Publications

  • Mallory RM, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, McFall H, Robinson M, Plested JS, Zhu M, Cloney-Clark S, Zhou B, Chau G, Robertson A, Maciejewski S, Hammond HL, Baracco L, Logue J, Frieman MB, Smith G, Patel N, Glenn GM; Novavax 2019nCoV101 Study Group. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect Dis. 2022 Nov;22(11):1565-1576. doi: 10.1016/S1473-3099(22)00420-0. Epub 2022 Aug 10. PubMed 35963274 ↗
  • Formica N, Mallory R, Albert G, Robinson M, Plested JS, Cho I, Robertson A, Dubovsky F, Glenn GM; 2019nCoV-101 Study Group. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. PLoS Med. 2021 Oct 1;18(10):e1003769. doi: 10.1371/journal.pmed.1003769. eCollection 2021 Oct. PubMed 34597298 ↗
  • Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, Smith G. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021 Jan 14;12(1):372. doi: 10.1038/s41467-020-20653-8. PubMed 33446655 ↗
  • Guebre-Xabier M, Patel N, Tian JH, Zhou B, Maciejewski S, Lam K, Portnoff AD, Massare MJ, Frieman MB, Piedra PA, Ellingsworth L, Glenn G, Smith G. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020 Nov 25;38(50):7892-7896. doi: 10.1016/j.vaccine.2020.10.064. Epub 2020 Oct 23. PubMed 33139139 ↗
  • Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2. PubMed 32877576 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Jun 2022, 24 months.

Of 80 industry-sponsored phase 1/2 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 24 months is above that.

Counting every sponsor, half of 187 studies reached it within 11 months; a quarter within 4 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2020
First posted
Apr 30, 2020
StartActual
May 25, 2020
Primary completionActual
Jun 1, 2022
CompletionActual
Jun 1, 2022
Results delay requested
Mar 29, 2023
Last update
Apr 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04368988
Lead sponsor
Novavax
Collaborators
Coalition for Epidemic Preparedness Innovations
Responsible party
Sponsor
First posted
Apr 30, 2020
Start date
May 25, 2020
Primary completion
Jun 1, 2022
Completion
Jun 1, 2022
Last update
Apr 10, 2023

Study contacts

Clinical Development
study director · Novavax

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion